OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

Completed · Phase 2

Conditions studied: Diarrhea

In brief

The purpose of this study is to investigate the safety and perform preliminary clinical evaluation in patients with mild to moderate CDAD.

Key facts

Study ID

NCT00097422

Run by

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Starts

2004-11-01

Expected to finish

2005-04-01

Last updated by the study team

2017-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with CDAD

You may not qualify if…

• Patients with severe CDAD

Where it is running

• Advanced Biologics — New Hope, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.